IL106760A0 - Translocation signal facilitated nuclear delivery of macromolecules - Google Patents
Translocation signal facilitated nuclear delivery of macromoleculesInfo
- Publication number
- IL106760A0 IL106760A0 IL106760A IL10676093A IL106760A0 IL 106760 A0 IL106760 A0 IL 106760A0 IL 106760 A IL106760 A IL 106760A IL 10676093 A IL10676093 A IL 10676093A IL 106760 A0 IL106760 A0 IL 106760A0
- Authority
- IL
- Israel
- Prior art keywords
- macromolecules
- translocation signal
- nuclear delivery
- facilitated nuclear
- signal facilitated
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Formation Of Insulating Films (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US93507492A | 1992-08-25 | 1992-08-25 |
Publications (2)
Publication Number | Publication Date |
---|---|
IL106760A0 true IL106760A0 (en) | 1993-12-08 |
IL106760A IL106760A (en) | 1999-12-31 |
Family
ID=25466554
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL10676093A IL106760A (en) | 1992-08-25 | 1993-08-22 | Protein-nucleic acid hybrid construct for translocating an exogenous nucleic acid into a target cell and nucleus |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP0658210A1 (en) |
JP (1) | JPH08504565A (en) |
KR (1) | KR950703650A (en) |
AU (1) | AU674026B2 (en) |
CA (1) | CA2143308A1 (en) |
FI (1) | FI950866A (en) |
IL (1) | IL106760A (en) |
NZ (1) | NZ255870A (en) |
WO (1) | WO1994004696A1 (en) |
ZA (1) | ZA936189B (en) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5674977A (en) * | 1993-02-05 | 1997-10-07 | The Ontario Cancer Institute | Branched synthetic peptide conjugate |
EP0693939A1 (en) * | 1993-04-14 | 1996-01-31 | Roche Diagnostics GmbH | Nucleic acid tranfer peptides and their use for injecting nucleic acids into eucaryotic cells |
EP0745134A1 (en) | 1994-02-22 | 1996-12-04 | Danafarber Cancer Institute | Nucleic acid delivery system, method of synthesis and uses thereof |
US6037329A (en) * | 1994-03-15 | 2000-03-14 | Selective Genetics, Inc. | Compositions containing nucleic acids and ligands for therapeutic treatment |
EP0753069A1 (en) * | 1994-04-15 | 1997-01-15 | Targeted Genetics Corporation | Gene delivery fusion proteins |
US6468981B1 (en) * | 1994-07-29 | 2002-10-22 | Emory University | Compositions and methods for targeting pharmaceutically active materials to cells containing androgen receptors |
WO1996013599A1 (en) * | 1994-11-01 | 1996-05-09 | Winfried Wels | Nucleic acid transfer system |
US6051429A (en) * | 1995-06-07 | 2000-04-18 | Life Technologies, Inc. | Peptide-enhanced cationic lipid transfections |
CA2251691A1 (en) * | 1996-03-26 | 1997-10-02 | Razvan T. Radulescu | Peptides with antiproliferative properties |
US5962415A (en) * | 1996-09-20 | 1999-10-05 | Bristol-Myers Squibb Co. | Compositions comprising a peptide inhibitor of nuclear protein translocation and an immunosuppressant and methods of use thereof |
US5877282A (en) * | 1996-09-20 | 1999-03-02 | Bristol-Myers Squibb Company | Peptide inhibitors of nuclear protein translocation having nuclear localization sequences and methods of use thereof |
DE19649645A1 (en) * | 1996-11-29 | 1998-06-04 | Hoechst Ag | Multiple functional ligand system for target cell-specific transfer of nucleotide sequences |
US6086900A (en) * | 1997-03-26 | 2000-07-11 | Board Of Regents, The University Of Texas Systems | Methods and compositions for using membrane-penetrating proteins to carry materials across cell membranes |
GB9713122D0 (en) * | 1997-06-20 | 1997-08-27 | Chiron Spa | Novel method of DNA transfer into cells |
WO1999007723A1 (en) * | 1997-08-07 | 1999-02-18 | University Of Maryland, Baltimore | Nucleic acid uptake and release vehicle |
US7166745B1 (en) | 1998-11-12 | 2007-01-23 | Invitrogen Corporation | Transfection reagents |
AU2983100A (en) * | 1999-02-06 | 2000-08-25 | Aurx, Inc. | Drug delivery vehicle |
DE19910419A1 (en) * | 1999-03-10 | 2000-09-21 | Aventis Pharma Gmbh | Target Cell-Specific Multivalent Proteins (MVP) |
FR2793414B1 (en) * | 1999-05-10 | 2003-05-23 | Centre Nat Rech Scient | NUCLEIC ACID-ANTIBODY CONJUGATE FOR DELIVERING FOREIGN NUCLEIC ACID TO CELLS |
US6387684B1 (en) * | 1999-09-13 | 2002-05-14 | Academia Sinica | Topoisomerase 1-mediated DNA delivery |
US8128922B2 (en) | 1999-10-20 | 2012-03-06 | Johns Hopkins University | Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen |
CA2388045C (en) * | 1999-10-20 | 2014-02-11 | Tzyy-Choou Wu | Nucleic acid immunogenic compositions encoding hsp-antigen chimera |
DE10019157A1 (en) * | 2000-04-18 | 2001-11-15 | Stefan Duebel | Method for introducing ligands into living cells |
ES2454640T3 (en) | 2000-08-03 | 2014-04-11 | Johns Hopkins University | Molecular vaccine that carries a chaperone polypeptide from the endoplasmic reticulum to an antigen |
US7198924B2 (en) | 2000-12-11 | 2007-04-03 | Invitrogen Corporation | Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites |
WO2002083166A1 (en) * | 2001-04-10 | 2002-10-24 | Santen Pharmaceutical Co., Ltd. | Interferon-polymer complexes and medicinal use thereof |
EP1947116B1 (en) * | 2003-02-10 | 2017-06-21 | 2-BBB Medicines B.V. | Differentially expressed nucleic acids in the blood-brain barrier under inflammatory conditions |
WO2004098526A2 (en) | 2003-05-05 | 2004-11-18 | Johns Hopkins University | Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein |
WO2005054438A2 (en) | 2003-12-01 | 2005-06-16 | Invitrogen Corporation | Nucleic acid molecules containing recombination sites and methods of using the same |
AU2005322960A1 (en) | 2005-01-06 | 2006-07-13 | The Johns Hopkins University | RNA interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by DNA and transfected dendritic cell vaccines |
US9085638B2 (en) | 2007-03-07 | 2015-07-21 | The Johns Hopkins University | DNA vaccine enhancement with MHC class II activators |
WO2010007593A1 (en) * | 2008-07-18 | 2010-01-21 | Chee Keong Choo | Methods of long-term culture of eukaryotic cells and uses thereof |
CN106572974B (en) | 2014-07-15 | 2021-04-23 | 生命技术公司 | Compositions and methods having lipid aggregates for efficient delivery of molecules to cells |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05505102A (en) * | 1989-12-21 | 1993-08-05 | ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ | How to deliver molecules into eukaryotic cells |
CA2092319A1 (en) * | 1990-09-25 | 1992-03-26 | George Y. Wu | Prolonging expression of polynucleotides introduced into a cell |
DE4139001A1 (en) * | 1991-11-27 | 1993-06-03 | Boehringer Mannheim Gmbh | PROCESS FOR INJECTION OF NUCLEAR ACIDS IN CELLS |
WO1993017102A1 (en) * | 1992-02-19 | 1993-09-02 | The Trustees Of The University Of Pennsylvania | MODULATIONS OF CELLULAR FUNCTIONS WITH HnRNP PROTEINS |
CA2131620A1 (en) * | 1992-03-20 | 1993-09-30 | Louis C. Smith | A dna transporter system and method of use |
-
1993
- 1993-08-22 IL IL10676093A patent/IL106760A/en not_active IP Right Cessation
- 1993-08-24 NZ NZ255870A patent/NZ255870A/en unknown
- 1993-08-24 KR KR1019950700814A patent/KR950703650A/en not_active Application Discontinuation
- 1993-08-24 ZA ZA936189A patent/ZA936189B/en unknown
- 1993-08-24 AU AU50885/93A patent/AU674026B2/en not_active Ceased
- 1993-08-24 WO PCT/US1993/007945 patent/WO1994004696A1/en not_active Application Discontinuation
- 1993-08-24 CA CA002143308A patent/CA2143308A1/en not_active Abandoned
- 1993-08-24 EP EP93920291A patent/EP0658210A1/en not_active Withdrawn
- 1993-08-24 JP JP6506592A patent/JPH08504565A/en active Pending
-
1995
- 1995-02-24 FI FI950866A patent/FI950866A/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU674026B2 (en) | 1996-12-05 |
FI950866A0 (en) | 1995-02-24 |
JPH08504565A (en) | 1996-05-21 |
KR950703650A (en) | 1995-09-20 |
ZA936189B (en) | 1995-01-10 |
WO1994004696A1 (en) | 1994-03-03 |
AU5088593A (en) | 1994-03-15 |
NZ255870A (en) | 1996-09-25 |
EP0658210A1 (en) | 1995-06-21 |
CA2143308A1 (en) | 1994-03-03 |
IL106760A (en) | 1999-12-31 |
FI950866A (en) | 1995-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA936189B (en) | Translocation signal facilitated nuclear delivery of macromolecules | |
IL105218A0 (en) | Hexanones and pharmaceutical compositions containing them | |
HU9303282D0 (en) | Pharmaceutical preparations containing hialuronic acid and/or derivatives and/or fragments | |
IL105223A0 (en) | Cyclohexane-ylidenes and pharmaceutical compositions containing them | |
EP0586256A3 (en) | Time measurement system | |
GB9226229D0 (en) | Detection of macromolecules | |
GB2264605B (en) | Signal compressing system | |
GB2255503B (en) | Improved use of ß2-bronchodilator drugs | |
HU9303283D0 (en) | Pharmaceutical preparations containing hialuronic acid and/or derivatives and/or fragments | |
IL106098A0 (en) | Heteroarylnaphthalenes and pharmaceutical compositions containing them | |
IL97122A0 (en) | Aromatase-inhibiting androstendiones and pharmaceutical compositions containing them | |
IL108073A0 (en) | Substituted 6-azaandrostenones their preparation and pharmaceutical compositions containing them | |
HU9300804D0 (en) | Pharmaceutical preparatives | |
AU587938B2 (en) | Combination counting and weighing system | |
PH25597A (en) | DISPENSING OF lIQWUID | |
HU9303025D0 (en) | 4-aryl-3(jheteroaryl-ureido)-quinoline derivatives and pharmaceutical preparatives containing them | |
IL104417A0 (en) | Substituted dihydroindene and-acenaphthene derivatives and pharmaceutical compositions containing them | |
IL108031A0 (en) | Difluoro pentapeptide derivatives and pharmaceutical compositions containing them | |
CZ87895A3 (en) | Pharmaceutical preparation | |
HUP9602220A3 (en) | Substituted 4h-piranes and pharmaceutical preparations containing them | |
ZA934523B (en) | Medicinal preparation | |
HU9203050D0 (en) | Thieno-cyclopentanole-oximes and pharmaceutical preparatives containing them | |
GB9222591D0 (en) | Medicinal remedy | |
IL106352A0 (en) | Pyridoindolo-benzodiazepines and pharmaceutical compositions containing them | |
PL298159A1 (en) | Pharmaceutical preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed | ||
RH1 | Patent not in force |